Clinical Trial Update: Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

View source ↗

Summary

Clinical trial update describing a managed access program for a combination treatment including belantamab mafodotin in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Status: AVAILABLE